Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients
Abstract Background. Immunomagnetic EpCAM based methods are used to enrich circulating tumor cells (CTCs) in metastatic breast cancer (mBC) patients. EpCAM negative CTCs may be missed. We addressed the question of the reliability of an EpCAM dependent assay to enrich CTCs. Methods. To elucidate this...
Gespeichert in:
| Veröffentlicht in: | Acta oncologica 2011-06, Vol.50 (5), p.700-710 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 710 |
|---|---|
| container_issue | 5 |
| container_start_page | 700 |
| container_title | Acta oncologica |
| container_volume | 50 |
| creator | Königsberg, Robert Obermayr, Eva Bises, Giovanna Pfeiler, Georg Gneist, Margit Wrba, Fritz de Santis, Maria Zeillinger, Robert Hudec, Marcus Dittrich, Christian |
| description | Abstract
Background. Immunomagnetic EpCAM based methods are used to enrich circulating tumor cells (CTCs) in metastatic breast cancer (mBC) patients. EpCAM negative CTCs may be missed. We addressed the question of the reliability of an EpCAM dependent assay to enrich CTCs. Methods. To elucidate this issue, our study has been designed to assess two different CTC enrichment technologies (i) in EpCAM positive (+) and EpCAM negative cell lines and (ii) in mBC patients in dependency on their respective EpCAM expression. These two technologies encompass one anti-EpCAM immunomagnetic enrichment technology, MACS HEA MicroBeads® (MACS), and one EpCAM independent density centrifugation method, OncoQuick® plus (OQ+). Furthermore, the coherence between EpCAM expression in the primary tumor tissue of mBC patients and the CTC detection rates in the corresponding patients is analyzed. Results. (i) MACS recovered significantly more EpCAM (+) than EpCAM (−) tumor cells (p < 0.001) in spiked blood samples. With OQ+ no significantly different recovery rates between EpCAM (+) and EpCAM (−) tumor cells (p = 0.796) were detected. (ii) In mBC patients MACS yielded a significantly higher (p = 0.024) detection rate of EpCAM (+) CTCs. No statistically significant difference (p = 0.070) was found concerning the EpCAM status-based detection rate of CTCs by OQ+. (iii) CTC detection rates are independent of the primary tumors' EpCAM expression. Conclusions. EpCAM (−) CTCs can not be detected by immunomagnetic EpCAM dependent enrichment methods. EpCAM independent enrichment technologies seem to be superior to detect the entire CTC population. Evaluation of CTCs as prognostic marker should compromise EpCAM (+) and (−) subpopulations. |
| doi_str_mv | 10.3109/0284186X.2010.549151 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_867477799</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>867477799</sourcerecordid><originalsourceid>FETCH-LOGICAL-c524t-e75f386ce4fc3b6c28d5433e1701c3da6af3de5f205cecf59aa435bb7d7a62693</originalsourceid><addsrcrecordid>eNp9kEtP3DAQgK2KqiyPf4CQb5yy-BHbyQUJLVtAAvXSStwsxxlDUGIH20Hi3zdhgSMnj2e-8Xg-hE4oWXNK6nPCqpJW8mHNyJwSZU0F_YFWVApaMCYf9tBqQYqF2UcHKT0TQhhX4hfaZ5RJKki1QnAFGWzugsfB4e24ubzHY0hd7l4BG99iD4_m_WK7aKd-jv0jztMQIrbQ9wl3Hg-QTcpzyeImwhxia7yFiMc5Bz6nI_TTmT7B8cd5iP793v7d3BR3f65vN5d3hRWszAUo4XglLZTO8kZaVrWi5ByoItTy1kjjeAvCMSIsWCdqY0oumka1ykgma36IznbvjjG8TJCyHrq0fNN4CFPSlVSlUqpeyHJH2hhSiuD0GLvBxDdNiV786k-_evGrd37nttOPAVMzQPvV9Cl0Bi52QOddiIN5AtPnJ2si6OcwRT9v__2E__Z-i4I</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>867477799</pqid></control><display><type>article</type><title>Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients</title><source>MEDLINE</source><source>Taylor & Francis:Master (3349 titles)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Königsberg, Robert ; Obermayr, Eva ; Bises, Giovanna ; Pfeiler, Georg ; Gneist, Margit ; Wrba, Fritz ; de Santis, Maria ; Zeillinger, Robert ; Hudec, Marcus ; Dittrich, Christian</creator><creatorcontrib>Königsberg, Robert ; Obermayr, Eva ; Bises, Giovanna ; Pfeiler, Georg ; Gneist, Margit ; Wrba, Fritz ; de Santis, Maria ; Zeillinger, Robert ; Hudec, Marcus ; Dittrich, Christian</creatorcontrib><description>Abstract
Background. Immunomagnetic EpCAM based methods are used to enrich circulating tumor cells (CTCs) in metastatic breast cancer (mBC) patients. EpCAM negative CTCs may be missed. We addressed the question of the reliability of an EpCAM dependent assay to enrich CTCs. Methods. To elucidate this issue, our study has been designed to assess two different CTC enrichment technologies (i) in EpCAM positive (+) and EpCAM negative cell lines and (ii) in mBC patients in dependency on their respective EpCAM expression. These two technologies encompass one anti-EpCAM immunomagnetic enrichment technology, MACS HEA MicroBeads® (MACS), and one EpCAM independent density centrifugation method, OncoQuick® plus (OQ+). Furthermore, the coherence between EpCAM expression in the primary tumor tissue of mBC patients and the CTC detection rates in the corresponding patients is analyzed. Results. (i) MACS recovered significantly more EpCAM (+) than EpCAM (−) tumor cells (p < 0.001) in spiked blood samples. With OQ+ no significantly different recovery rates between EpCAM (+) and EpCAM (−) tumor cells (p = 0.796) were detected. (ii) In mBC patients MACS yielded a significantly higher (p = 0.024) detection rate of EpCAM (+) CTCs. No statistically significant difference (p = 0.070) was found concerning the EpCAM status-based detection rate of CTCs by OQ+. (iii) CTC detection rates are independent of the primary tumors' EpCAM expression. Conclusions. EpCAM (−) CTCs can not be detected by immunomagnetic EpCAM dependent enrichment methods. EpCAM independent enrichment technologies seem to be superior to detect the entire CTC population. Evaluation of CTCs as prognostic marker should compromise EpCAM (+) and (−) subpopulations.</description><identifier>ISSN: 0284-186X</identifier><identifier>EISSN: 1651-226X</identifier><identifier>DOI: 10.3109/0284186X.2010.549151</identifier><identifier>PMID: 21261508</identifier><language>eng</language><publisher>England: Informa Healthcare</publisher><subject>Adult ; Aged ; Antigens, Neoplasm - blood ; Antigens, Neoplasm - metabolism ; Biomarkers, Tumor - metabolism ; Breast Neoplasms - diagnosis ; Breast Neoplasms - metabolism ; Breast Neoplasms - pathology ; Carcinoma - diagnosis ; Carcinoma - metabolism ; Carcinoma - pathology ; Case-Control Studies ; Cell Adhesion Molecules - blood ; Cell Adhesion Molecules - metabolism ; Cell Line, Tumor ; Cell Separation - methods ; Epithelial Cell Adhesion Molecule ; Female ; Humans ; Middle Aged ; Neoplasm Metastasis ; Neoplastic Cells, Circulating - metabolism ; Neoplastic Cells, Circulating - pathology ; Prognosis ; Sensitivity and Specificity</subject><ispartof>Acta oncologica, 2011-06, Vol.50 (5), p.700-710</ispartof><rights>2011 Informa Healthcare 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c524t-e75f386ce4fc3b6c28d5433e1701c3da6af3de5f205cecf59aa435bb7d7a62693</citedby><cites>FETCH-LOGICAL-c524t-e75f386ce4fc3b6c28d5433e1701c3da6af3de5f205cecf59aa435bb7d7a62693</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.3109/0284186X.2010.549151$$EPDF$$P50$$Ginformahealthcare$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.3109/0284186X.2010.549151$$EHTML$$P50$$Ginformahealthcare$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,61221,61402</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21261508$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Königsberg, Robert</creatorcontrib><creatorcontrib>Obermayr, Eva</creatorcontrib><creatorcontrib>Bises, Giovanna</creatorcontrib><creatorcontrib>Pfeiler, Georg</creatorcontrib><creatorcontrib>Gneist, Margit</creatorcontrib><creatorcontrib>Wrba, Fritz</creatorcontrib><creatorcontrib>de Santis, Maria</creatorcontrib><creatorcontrib>Zeillinger, Robert</creatorcontrib><creatorcontrib>Hudec, Marcus</creatorcontrib><creatorcontrib>Dittrich, Christian</creatorcontrib><title>Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients</title><title>Acta oncologica</title><addtitle>Acta Oncol</addtitle><description>Abstract
Background. Immunomagnetic EpCAM based methods are used to enrich circulating tumor cells (CTCs) in metastatic breast cancer (mBC) patients. EpCAM negative CTCs may be missed. We addressed the question of the reliability of an EpCAM dependent assay to enrich CTCs. Methods. To elucidate this issue, our study has been designed to assess two different CTC enrichment technologies (i) in EpCAM positive (+) and EpCAM negative cell lines and (ii) in mBC patients in dependency on their respective EpCAM expression. These two technologies encompass one anti-EpCAM immunomagnetic enrichment technology, MACS HEA MicroBeads® (MACS), and one EpCAM independent density centrifugation method, OncoQuick® plus (OQ+). Furthermore, the coherence between EpCAM expression in the primary tumor tissue of mBC patients and the CTC detection rates in the corresponding patients is analyzed. Results. (i) MACS recovered significantly more EpCAM (+) than EpCAM (−) tumor cells (p < 0.001) in spiked blood samples. With OQ+ no significantly different recovery rates between EpCAM (+) and EpCAM (−) tumor cells (p = 0.796) were detected. (ii) In mBC patients MACS yielded a significantly higher (p = 0.024) detection rate of EpCAM (+) CTCs. No statistically significant difference (p = 0.070) was found concerning the EpCAM status-based detection rate of CTCs by OQ+. (iii) CTC detection rates are independent of the primary tumors' EpCAM expression. Conclusions. EpCAM (−) CTCs can not be detected by immunomagnetic EpCAM dependent enrichment methods. EpCAM independent enrichment technologies seem to be superior to detect the entire CTC population. Evaluation of CTCs as prognostic marker should compromise EpCAM (+) and (−) subpopulations.</description><subject>Adult</subject><subject>Aged</subject><subject>Antigens, Neoplasm - blood</subject><subject>Antigens, Neoplasm - metabolism</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Breast Neoplasms - diagnosis</subject><subject>Breast Neoplasms - metabolism</subject><subject>Breast Neoplasms - pathology</subject><subject>Carcinoma - diagnosis</subject><subject>Carcinoma - metabolism</subject><subject>Carcinoma - pathology</subject><subject>Case-Control Studies</subject><subject>Cell Adhesion Molecules - blood</subject><subject>Cell Adhesion Molecules - metabolism</subject><subject>Cell Line, Tumor</subject><subject>Cell Separation - methods</subject><subject>Epithelial Cell Adhesion Molecule</subject><subject>Female</subject><subject>Humans</subject><subject>Middle Aged</subject><subject>Neoplasm Metastasis</subject><subject>Neoplastic Cells, Circulating - metabolism</subject><subject>Neoplastic Cells, Circulating - pathology</subject><subject>Prognosis</subject><subject>Sensitivity and Specificity</subject><issn>0284-186X</issn><issn>1651-226X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtP3DAQgK2KqiyPf4CQb5yy-BHbyQUJLVtAAvXSStwsxxlDUGIH20Hi3zdhgSMnj2e-8Xg-hE4oWXNK6nPCqpJW8mHNyJwSZU0F_YFWVApaMCYf9tBqQYqF2UcHKT0TQhhX4hfaZ5RJKki1QnAFGWzugsfB4e24ubzHY0hd7l4BG99iD4_m_WK7aKd-jv0jztMQIrbQ9wl3Hg-QTcpzyeImwhxia7yFiMc5Bz6nI_TTmT7B8cd5iP793v7d3BR3f65vN5d3hRWszAUo4XglLZTO8kZaVrWi5ByoItTy1kjjeAvCMSIsWCdqY0oumka1ykgma36IznbvjjG8TJCyHrq0fNN4CFPSlVSlUqpeyHJH2hhSiuD0GLvBxDdNiV786k-_evGrd37nttOPAVMzQPvV9Cl0Bi52QOddiIN5AtPnJ2si6OcwRT9v__2E__Z-i4I</recordid><startdate>20110601</startdate><enddate>20110601</enddate><creator>Königsberg, Robert</creator><creator>Obermayr, Eva</creator><creator>Bises, Giovanna</creator><creator>Pfeiler, Georg</creator><creator>Gneist, Margit</creator><creator>Wrba, Fritz</creator><creator>de Santis, Maria</creator><creator>Zeillinger, Robert</creator><creator>Hudec, Marcus</creator><creator>Dittrich, Christian</creator><general>Informa Healthcare</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110601</creationdate><title>Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients</title><author>Königsberg, Robert ; Obermayr, Eva ; Bises, Giovanna ; Pfeiler, Georg ; Gneist, Margit ; Wrba, Fritz ; de Santis, Maria ; Zeillinger, Robert ; Hudec, Marcus ; Dittrich, Christian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c524t-e75f386ce4fc3b6c28d5433e1701c3da6af3de5f205cecf59aa435bb7d7a62693</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antigens, Neoplasm - blood</topic><topic>Antigens, Neoplasm - metabolism</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Breast Neoplasms - diagnosis</topic><topic>Breast Neoplasms - metabolism</topic><topic>Breast Neoplasms - pathology</topic><topic>Carcinoma - diagnosis</topic><topic>Carcinoma - metabolism</topic><topic>Carcinoma - pathology</topic><topic>Case-Control Studies</topic><topic>Cell Adhesion Molecules - blood</topic><topic>Cell Adhesion Molecules - metabolism</topic><topic>Cell Line, Tumor</topic><topic>Cell Separation - methods</topic><topic>Epithelial Cell Adhesion Molecule</topic><topic>Female</topic><topic>Humans</topic><topic>Middle Aged</topic><topic>Neoplasm Metastasis</topic><topic>Neoplastic Cells, Circulating - metabolism</topic><topic>Neoplastic Cells, Circulating - pathology</topic><topic>Prognosis</topic><topic>Sensitivity and Specificity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Königsberg, Robert</creatorcontrib><creatorcontrib>Obermayr, Eva</creatorcontrib><creatorcontrib>Bises, Giovanna</creatorcontrib><creatorcontrib>Pfeiler, Georg</creatorcontrib><creatorcontrib>Gneist, Margit</creatorcontrib><creatorcontrib>Wrba, Fritz</creatorcontrib><creatorcontrib>de Santis, Maria</creatorcontrib><creatorcontrib>Zeillinger, Robert</creatorcontrib><creatorcontrib>Hudec, Marcus</creatorcontrib><creatorcontrib>Dittrich, Christian</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Acta oncologica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Königsberg, Robert</au><au>Obermayr, Eva</au><au>Bises, Giovanna</au><au>Pfeiler, Georg</au><au>Gneist, Margit</au><au>Wrba, Fritz</au><au>de Santis, Maria</au><au>Zeillinger, Robert</au><au>Hudec, Marcus</au><au>Dittrich, Christian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients</atitle><jtitle>Acta oncologica</jtitle><addtitle>Acta Oncol</addtitle><date>2011-06-01</date><risdate>2011</risdate><volume>50</volume><issue>5</issue><spage>700</spage><epage>710</epage><pages>700-710</pages><issn>0284-186X</issn><eissn>1651-226X</eissn><abstract>Abstract
Background. Immunomagnetic EpCAM based methods are used to enrich circulating tumor cells (CTCs) in metastatic breast cancer (mBC) patients. EpCAM negative CTCs may be missed. We addressed the question of the reliability of an EpCAM dependent assay to enrich CTCs. Methods. To elucidate this issue, our study has been designed to assess two different CTC enrichment technologies (i) in EpCAM positive (+) and EpCAM negative cell lines and (ii) in mBC patients in dependency on their respective EpCAM expression. These two technologies encompass one anti-EpCAM immunomagnetic enrichment technology, MACS HEA MicroBeads® (MACS), and one EpCAM independent density centrifugation method, OncoQuick® plus (OQ+). Furthermore, the coherence between EpCAM expression in the primary tumor tissue of mBC patients and the CTC detection rates in the corresponding patients is analyzed. Results. (i) MACS recovered significantly more EpCAM (+) than EpCAM (−) tumor cells (p < 0.001) in spiked blood samples. With OQ+ no significantly different recovery rates between EpCAM (+) and EpCAM (−) tumor cells (p = 0.796) were detected. (ii) In mBC patients MACS yielded a significantly higher (p = 0.024) detection rate of EpCAM (+) CTCs. No statistically significant difference (p = 0.070) was found concerning the EpCAM status-based detection rate of CTCs by OQ+. (iii) CTC detection rates are independent of the primary tumors' EpCAM expression. Conclusions. EpCAM (−) CTCs can not be detected by immunomagnetic EpCAM dependent enrichment methods. EpCAM independent enrichment technologies seem to be superior to detect the entire CTC population. Evaluation of CTCs as prognostic marker should compromise EpCAM (+) and (−) subpopulations.</abstract><cop>England</cop><pub>Informa Healthcare</pub><pmid>21261508</pmid><doi>10.3109/0284186X.2010.549151</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0284-186X |
| ispartof | Acta oncologica, 2011-06, Vol.50 (5), p.700-710 |
| issn | 0284-186X 1651-226X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_867477799 |
| source | MEDLINE; Taylor & Francis:Master (3349 titles); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Adult Aged Antigens, Neoplasm - blood Antigens, Neoplasm - metabolism Biomarkers, Tumor - metabolism Breast Neoplasms - diagnosis Breast Neoplasms - metabolism Breast Neoplasms - pathology Carcinoma - diagnosis Carcinoma - metabolism Carcinoma - pathology Case-Control Studies Cell Adhesion Molecules - blood Cell Adhesion Molecules - metabolism Cell Line, Tumor Cell Separation - methods Epithelial Cell Adhesion Molecule Female Humans Middle Aged Neoplasm Metastasis Neoplastic Cells, Circulating - metabolism Neoplastic Cells, Circulating - pathology Prognosis Sensitivity and Specificity |
| title | Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T23%3A52%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Detection%20of%20EpCAM%20positive%20and%20negative%20circulating%20tumor%20cells%20in%20metastatic%20breast%20cancer%20patients&rft.jtitle=Acta%20oncologica&rft.au=K%C3%B6nigsberg,%20Robert&rft.date=2011-06-01&rft.volume=50&rft.issue=5&rft.spage=700&rft.epage=710&rft.pages=700-710&rft.issn=0284-186X&rft.eissn=1651-226X&rft_id=info:doi/10.3109/0284186X.2010.549151&rft_dat=%3Cproquest_cross%3E867477799%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=867477799&rft_id=info:pmid/21261508&rfr_iscdi=true |